Vortioxetine for Post-COVID-19 Condition
Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Vortioxetine for Cognitive Deficits in Persons With Post-COVID-19 Condition
Sponsor: Brain and Cognition Discovery Foundation
Listed as NCT05047952, this PHASE2 trial focuses on Cognitive Impairment and Post-COVID-19 Condition and remains completed. Sponsored by Brain and Cognition Discovery Foundation, it has been updated 7 times since 2021, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Feb 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Feb 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Sep 2022 — Jun 2023 [monthly]
Recruiting PHASE2
▶ Show 2 earlier versions
-
Apr 2022 — Sep 2022 [monthly]
Recruiting PHASE2
-
Oct 2021 — Apr 2022 [monthly]
Recruiting PHASE2
First recorded
Sep 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Brain and Cognition Discovery Foundation
For direct contact, visit the study record on ClinicalTrials.gov .